» Articles » PMID: 32275454

Inutility of Endoscopic Sphincterotomy to Prevent Pancreatitis After Biliary Metal Stent Placement in the Patients Without Pancreatic Duct Obstruction

Overview
Publisher Informa Healthcare
Specialty Gastroenterology
Date 2020 Apr 11
PMID 32275454
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The incidence of post-ERCP pancreatitis (PEP) has been reported to be significantly higher in patients without main pancreatic duct (MPD) obstruction who undergo transpapillary biliary metal stent (MS) placement than in those with ordinary ERCP setting. To evaluate the benefit of endoscopic sphincterotomy (ES) prior to MS placement in preventing PEP in patients with distal malignant biliary obstruction (MBO) without MPD obstruction. In total, 160 patients who underwent initial MS placement for MBO were enrolled. Eighty-two patients underwent ES immediately prior to MS placement, whereas 78 underwent MS placement without ES. An inverse probability of treatment weighting method was adopted to adjust the differences of the patients' characteristics. The primary outcome was the incidence of PEP. The secondary outcomes included the incidence of other adverse events (bleeding, cholangitis, perforation and stent dislocation) and time to recurrent biliary obstruction. The incidence of PEP was 26.8% in the ES and 23.1% in the non-ES (unadjusted odds ratio [OR] [95%CI]: 1.22, [0.60-2.51], adjusted OR [95%CI]: 1.23, [0.53-2.81],  = .63). Logistic-regression analysis revealed no factors that could be attributed to the occurrence of PEP. The incidence of other adverse events was not different between the groups. The median time to recurrent biliary obstruction was 131 (2-465) days and 200 (4-864) days in the ES and non-ES, respectively ( = .215). ES prior to MS placement for patients with distal MBO without MPD obstruction does not reduce the incidence of PEP.

Citing Articles

Does endoscopic sphincterotomy contribute to the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis after endoscopic biliary stenting for malignant biliary obstruction? A multicenter prospective cohort study.

Nebiki H, Fujita K, Yazumi S, Takenaka M, Maruo T, Matsumoto K Surg Endosc. 2022; 37(5):3463-3470.

PMID: 36575219 DOI: 10.1007/s00464-022-09823-5.


A Risk Prediction Model for Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis After Stent Insertion for Malignant Biliary Obstruction: Development and Validation.

Fu Z, Song J, Pi Y, Sun X, Liu M, Xiao Z Dig Dis Sci. 2022; 68(4):1574-1584.

PMID: 35989385 DOI: 10.1007/s10620-022-07649-8.


Evaluation of post-ERCP pancreatitis after biliary stenting with self-expandable metal stents vs. plastic stents in benign and malignant obstructions.

Martinez N, Inamdar S, Firoozan S, Izard S, Lee C, Benias P Endosc Int Open. 2021; 9(6):E888-E894.

PMID: 34079872 PMC: 8159589. DOI: 10.1055/a-1388-6964.